Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Interleukin Genetics has entered into a research collaboration with Metagenics to identify predictive biomarkers combinations for use with Metagenics compound Meta-060 in development for weight management.
Subscribe to our email newsletter
Meta-060 is a proprietary and patented formulation of tetrahydro iso-alpha acids derived from hops.
The collaboration is to investigate if genetic variations identified by Interleukin Genetics are beneficial to improving weight loss and maintenance of weight loss in adults using Meta-060.
Interleukin Genetics products include proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies effective diet and exercise program for an individual based on genetics.
Interleukin Genetics CEO Lewis Bender said they believe this research could create useful prognostic tests that can be used with treatments such as the Metagenics compound to better manage an individual’s weight.
"We also expect that the data generated from this study will provide a new tool in the development of improved treatments for obesity, a clear unmet medical need in personalizing disease management," Bender said.